Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials.

Abstract

PURPOSE Intravenous vinflunine 320 mg/m(2) every 3 weeks plus best supportive care resulted in better overall survival in comparison with best supportive care alone for eligible patients with failure of prior therapy with locally advanced or metastatic transitional cell cancer of urothelial tract (TCCU). The objective of the present study was to describe… (More)
DOI: 10.1016/j.clgc.2015.05.008

Topics

Cite this paper

@article{Moriceau2015RealWorldVO, title={Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials.}, author={Guillaume Moriceau and Alexis Vallard and Romain Rivoirard and Beno{\^i}te M{\'e}ry and Sophie Espenel and Julien Langrand-Escure and Majed Ben Mrad and Guoping Wang and Peng Diao and C{\'e}cile Pacaut and Aline Guillot and Olivier Collard and Pierre Fournel and Nicolas Magn{\'e}}, journal={Clinical genitourinary cancer}, year={2015}, volume={13 6}, pages={588-92} }